Is GRCE or GYRE more undervalued in 2026?

CirclFi compares Grace Therapeutics, Inc. (GRCE) and Gyre Therapeutics, Inc. (GYRE) using 13 institutional-grade valuation models. GRCE has a Quality of Company score of 4.6/10 while GYRE scores 8.0/10.

Which is a better buy — GRCE or GYRE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRCE and GYRE valuations compare?

GRCE at $2.43 and GYRE at $5.74 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRCE vs GYRE Valuation Comparison 2026 — Intrinsic Value Analysis

GRCE

Biotechnology

Grace Therapeutics, Inc.

Quality

4.6

out of 10

Value Trap

WARN

Price

$2.43

Last close

Models

7/13

Active

GYRE

Biotechnology

Gyre Therapeutics, Inc.

Quality

8.0

out of 10

Value Trap

SAFE

Price

$5.74

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GRCE Fair Value	GRCE Upside	GYRE Fair Value	GYRE Upside
Bayesian DCF	Intrinsic	$1.31	-46.0%	$0.52	-90.9%
Earnings Power Value	Intrinsic	—	—	$0.74	-87.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$4.05	+66.7%	$1.15	-80.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRCE vs GYRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRCE vs GYRE — Which Stock Is More Undervalued?

GYRE scores higher with a 8.0/10 quality rating vs GRCE's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Grace Therapeutics, Inc. (GRCE) and Gyre Therapeutics, Inc. (GYRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRCE currently trades at $2.43 with a QOC of 4.6/10, while GYRE trades at $5.74 with a QOC of 8.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).